NCT07457918Phase 3Recruiting

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Study sponsor: Verrica Pharmaceuticals Inc. · VRCA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-11Estimated
Enrollment · participants250Estimated
Source updated2026-10-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment decreased by 350 participants

Before: 600 participants (planned). After: 250 participants (planned).

Primary completion date changed

Before: 30 Apr 2028. After: Nov 2027.

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source